Abstract
Aim: To investigate the influence of overt hyperthyroidism and euthyroid congenital hypothyroidism on fasting glucagon-like peptide-1 (GLP-1) levels.
Methods: A total of 30 untreated overt hyperthyroidism patients, 17 euthyroid congenital hypothyroidism children, and age- and sex-matched controls were enrolled. Levels of GLP-1, insulin, glucose, and homeostasis model assessment (HOMA-IR) were measured and evaluated.
Results: Fasting GLP-1, blood glucose, insulin, and HOMR-IR levels were higher in patients with overt hyperthyroidism than in controls (p=0.030, p=0.008, p=0.004, p=0.037, respectively). These parameters in euthyroid hypothyroidism were similar to the controls. In euthyroid congenital hypothyroidism and overt hyperthyroidism patients, serum GLP-1 levels were not correlated with thyroid hormone, blood glucose, insulin, and HOMR-IR.
Conclusions: Fasting GLP-1 levels in the peripheral circulation were significantly increased in overt hyperthyroidism, however, they were no different in euthyroid congenital hypothyroidism.
References
1. Kieffer JT, Habener FJ. The glucagon-like peptides. Endocr Rev 1999;20:876–913.10.1210/edrv.20.6.0385Search in Google Scholar
2. Heo KS, Fujiwara K, Abe J. Glucagon-like peptide-1 and its cardiovascular effects. Curr Atheroscler Rep 2012;14:422–8.10.1007/s11883-012-0265-9Search in Google Scholar
3. Yerram P, Whaley-Connell A. Novel role for the incretins in blood pressure regulation. Curr Opin Nephrol Hypertens 2012;21:463–8.10.1097/MNH.0b013e328356bccdSearch in Google Scholar
4. Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012;26:871–82.10.2165/11635890-000000000-00000Search in Google Scholar
5. Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160: 785–90.10.1530/EJE-08-0797Search in Google Scholar
6. Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, et al. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol 2010;163: 625–30.10.1530/EJE-10-0246Search in Google Scholar
7. Sawicka B, Bossowski A, Szalecki M, Wysoka J, Koput A, et al. Relationship between metabolic parameters and thyroid hormones and the level of gastric peptides in children with autoimmune thyroid diseases. J Pediatr Endocrinol Metab 2010;23:345–54.10.1515/jpem.2010.055Search in Google Scholar
8. Alioğlu B, Kılıç N, Şimşek E, Dallar Y. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism. J Clin Res Pediatr Endocrinol 2012;4: 146–50.10.4274/Jcrpe.652Search in Google Scholar
9. Ma SG, Fang PH, Hong B, Yu WN. The R450H mutation and D727E polymorphism of the thyrotropin receptor gene in a Chinese child with congenital hypothyroidism. J Pediatr Endocrinol Metab 2010;23:1339–44.Search in Google Scholar
10. Ma SG, Wu XJ, Liu H, Xu W, He L. Mutations of the thyroid peroxidase gene in Chinese siblings with congenital goitrous hypothyroidism. Arq Bras Endocrinol Metabol 2012;56:614–7.10.1590/S0004-27302012000900003Search in Google Scholar
11. Jung H, Hong Y, Lee D, Pang K, Kim Y. The association between some endocrine disruptors in human plasma and the occurrence of congenital hypothyroidism. Environ Toxicol Pharmacol 2013;35:278–83.10.1016/j.etap.2013.01.002Search in Google Scholar
12. Farahani H, Ghasemi A, Roghani M, Zahediasl S. Effect of neonatal hypothyroidism on carbohydrate metabolism, insulin secretion, and pancreatic islets morphology of adult male offspring in rats. J Endocrinol Invest 2013;36:44–9.Search in Google Scholar
13. DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 2002;56:101–6.10.1016/S0168-8227(01)00359-XSearch in Google Scholar
14. Zhang F, Tang X, Cao H, Lü Q, Li N, et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 2012;9:574–81.10.7150/ijms.4128Search in Google Scholar
15. Vaidyanathan P, Pathak M, Kaplowitz PB. In congenital hypothyroidism, an initial L-thyroxine dose of 10-12 μg/kg/day is sufficient and sometimes excessive based on thyroid tests 1 month later. J Pediatr Endocrinol Metab 2012;25:849–52.10.1515/jpem-2012-0025Search in Google Scholar
16. Tatsch E, Bochi GV, Piva SJ, Pereira RS, Kober H, et al. Hba(1c) as a tool for the diagnosis of type 2 diabetes: comparison with fasting glucose. Clin Lab 2012;58:347–50.Search in Google Scholar
17. Yu Y, Ouyang XJ, Lou QL, Gu LB, Mo YZ, et al. Validity of glycated hemoglobin in screening and diagnosing type 2 diabetes mellitus in Chinese subjects. Korean J Intern Med 2012;27: 41–6.10.3904/kjim.2012.27.1.41Search in Google Scholar
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.10.1007/BF00280883Search in Google Scholar
19. Siemińska L, Foltyn W, Głogowska-Szeląg J, Kajdaniuk D, Marek B, et al. Relationships between adiponectin, sex hormone binding globulin and insulin resistance in hyperthyroid Graves’ disease women. Endokrynol Pol 2013;64:26–9.Search in Google Scholar
20. Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism 2009;58:586–93.10.1016/j.metabol.2008.11.009Search in Google Scholar
21. Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol 2008;159:121–7.10.1530/EJE-08-0097Search in Google Scholar
22. Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013;56:965–72.10.1007/s00125-013-2841-0Search in Google Scholar
23. Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf) 2008;69:963–9.10.1111/j.1365-2265.2008.03280.xSearch in Google Scholar
24. Kubicky RA, Weiner E, Carlson B, De Luca F. Effect of prolonged discontinuation of L-thyroxine replacement in a child with congenital hypothyroidism. Case Rep Endocrinol 2012;2012:841947.10.1155/2012/841947Search in Google Scholar
25. Maitusong R, Japaer R, Zhao ZY, Yang RL, Huang XL, et al. Newborn screening in Zhejiang, China. Chin Med J (Engl) 2012;125:702–4.Search in Google Scholar
26. Gheissari A, Hashemipour M, Khosravi P, Adibi A. Different aspects of kidney function in well-controlled congenital hypothyroidism. J Clin Res Pediatr Endocrinol 2012;4: 193–8.10.4274/Jcrpe.811Search in Google Scholar
27. Akin MA, Aydogan S, Gunes T, Artis AS, Karakukcu M, et al. Changes of red blood cell rheology in newborns with congenital hypothyroidism during treatment. J Matern Fetal Neonatal Med 2013; doi:10.3109/14767058.2013.791270.10.3109/14767058.2013.791270Search in Google Scholar
©2013 by Walter de Gruyter Berlin Boston